SB 204990
Chemical Name: (3R,5S)-rel-5-[6-(2,4-Dichlorophenyl)hexyl]tetrahydro-3-hydroxy-2-oxo-3-furanacetic acid
Purity: ≥98%
Biological Activity
SB 204990 is an ATP citrate lyase (ACLY) inhibitor; it is a prodrug of SB 201076. SB 204990 inhibits cholesterol and fatty acid synthesis in a dose-dependent manner in HepG2 cells. Suppresses growth of cancer cells showing aerobic glycolysis in vitro and in vivo. Orally active.Technical Data
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Additional Information
Background References
-
Active mitochondria support osteogenic differentiation by stimulating ?-catenin acetylation
BH Shares, M Busch, N White, L Shum, RA Eliseev
J. Biol. Chem., 2018;0(0):. -
The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076.
Pearce et al.
Biochem.J., 1998;334:113 -
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R*,5S*)-ω-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzy
Gribble et al.
J.Med.Chem., 1998;41:3582
Product Datasheets
Citations for SB 204990
The citations listed below are publications that use Tocris products. Selected citations for SB 204990 include:
6 Citations: Showing 1 - 6
-
Acly Deficiency Enhances Myelopoiesis through Acetyl Coenzyme A and Metabolic�Epigenetic Cross-Talk
Authors: Greenwood Et al.
Immunohorizons 2022;6:837
-
The short-chain fatty acid acetate modulates epithelial-to-mesenchymal transition.
Authors: Yuesheng Et al.
Mol Biol Cell 2022;33
-
Phosphorylation of eukaryotic initiation factor-2α (eIF2α) in autophagy.
Authors: Guido Et al.
Cell Death Dis 2020;11:433
-
Polarization of Human Macrophages by Interleukin-4 Does Not Require ATP-Citrate Lyase.
Authors: Namgaladze Et al.
Front Immunol 2018;9:2858
-
Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.
Authors: Chen Et al.
Nat Genet 2018;50:219
-
Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism.
Authors: Shah Et al.
Oncotarget 2016;7:43713
FAQs
No product specific FAQs exist for this product, however you may
View all Small Molecule FAQsReviews for SB 204990
Average Rating: 5 (Based on 1 Review)
Have you used SB 204990?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
SB-204990 were used as an ACLY inhibitor in subconfluent endothelial cells. The images are shown in the publication PubMed ID 29429925.
